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ABSTRACT AND KEYWORDS 
 
Introduction and hypothesis: Pelvic organ prolapse (POP) surgery is an 
increasingly important aspect of gynecological practice. This study aims to characterize 
the evolution of POP surgical procedures conducted in Portugal in the last decade and 
the impact of FDA 2011 safety communication on mesh POP surgeries. 
Methods: Trends in surgical management of POP were assessed using the 
Portuguese National Medical Registry. We considered all records of women with 
diagnosis of genital prolapse from January 1, 2000 to December 31, 2012. Additionally, 
we also conducted a survey among members of the Portuguese Society of 
Urogynecology to evaluate current practices on surgical management of POP. 
Results: From 2000 to 2012, 46,819 diagnoses of genital prolapse were 
registered, with a 105% increase during the study period (2,368 in 2000 to 4,941 in 
2012). POP mesh surgery represented only 6% of total prolapse diagnoses, but mesh 
use greatly increased up to 2011, when only a slight increase was registered. Among 
gynecologists who responded to the questionnaire, there was considerable variability 
on the procedures of choice to treat POP. 57% of respondents performed vaginal mesh 
POP surgery, but only 27% of those actually reported having changed their practice 
after FDA 2011 safety communication. 
Conclusions: POP surgical procedures conducted in Portugal greatly increased 
during the last decade. The use of surgical meshes is still limited, but despite FDA 
safety communication it has increased over the years, with a slight increase in 2012 
that portraits the need for further analyses in the coming years. 
 
Keywords: Pelvic Organ Prolapse – Surgical Management – Vaginal Mesh 
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BRIEF SUMMARY 
Pelvic organ prolapse surgeries conducted in Portugal greatly increased during the last 
decade, but mesh use still limited. FDA communication had limited impact in Portugal.  
 
ABBREVIATIONS 
FDA  Food and Drug Administration 
ICD-9-CM International Classification of Diseases, 9th Revision, Clinical Modification 
IUGA  International Urogynecological Association 
POP  Pelvic organ prolapse 
PSUG  Portuguese Society of Urogynecology   
SPG  Portuguese Society of Gynecology   
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INTRODUCTION 
Pelvic organ prolapse (POP) is a fairly common medical condition worldwide. It 
affects approximately 40% of women older than 50 years, of which only 25% are 
symptomatic [1]. The estimated lifetime risk of undergoing POP surgery is 19% [2], 
which is approximately the double of risk reported in 1990; this increase is perceived as 
a consequence of population aging and greater awareness of this condition. 
Prolapse surgery is an increasingly important aspect of gynecological practice [3]. 
Over the years, surgical treatment of POP has greatly evolved, and now a variety of 
surgical techniques are available, but there is not yet definitive evidence on which 
techniques present the best treatment outcomes [4]. Therefore, the choice of the 
surgical technique to employ is mostly based on personal experience and training of 
the surgeon, rather than systematically collected data on the different techniques. 
Historically, surgeons relied on patients native tissues to perform repairs, such as 
anterior and/or posterior colporrhaphy and apical suspensions [5]. However, high 
recurrence rates were observed, probably due to poor tissue quality [6]. This led to 
introduction of surgical meshes, which replaced supportive tissue [7]. These surgical 
meshes were widely used for transvaginal POP repair over the last decade, but their 
application remains controversial [8]. In 2008, the US Food and Drug Administration 
(FDA) issued a public health notification raising some doubts about the safety of 
surgical meshes for transvaginal POP surgery [9]. Still, at this point the FDA concluded 
that serious adverse events were rare [9]. However, in 2011, the FDA published an 
updated communication, which included a literature review [10]. This time, the 
conclusion was that adverse events associated with mesh use are not rare and that 
there is no definitive evidence that mesh use improves clinical outcomes in comparison 
with traditional non-mesh repair [10]. This led to a reappraisal of the role of transvaginal 
mesh in POP surgery both within the US and other countries, with the ultimate goal of 
maximizing patient outcomes and safety [4,5,8,11,12].  
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This study aims to characterize the evolution of POP surgical procedures 
conducted in Portugal in the past decade (2000–2012) and to evaluate the current 
practices on POP surgery. Furthermore, the study also aims to assess the general 
impact of FDA 2011 safety communication on mesh POP surgeries, in particular the 
impact among Portuguese gynecologists with special interest in urogynecology.        
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METHODS 
National medical registry 
Trends in the surgical management of POP were assessed using data from the 
Portuguese National Medical Registry (clinical-administrative data), which is managed 
by the Central Administration of the National Health System. This registry contains 
information on diagnoses and procedures performed in acute care public hospitals in 
Portugal, as recorded at patient discharge. The International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) coding of both diagnoses and surgical 
procedures is done by trained coders. Additionally, coding is subjected to regular 
quality control audits [13]. 
We considered all records of women with a principal (primary) or secondary 
diagnosis of genital prolapse, ICD-9-CM code 618.xx, with discharge date from 
January 1, 2000 to December 31, 2012. Surgical procedures associated these ICD-9-
CM code 618.xx diagnoses were also assessed.  
Codes for the diagnosis of prolapse included the following: 618.0 prolapse of 
vaginal walls without mention of uterine prolapse; 618.1 uterine prolapse without 
mention of vaginal wall prolapse; 618.2 uterovaginal prolapse, incomplete; 618.3 
uterovaginal prolapse, complete; 618.4 uterovaginal prolapse, unspecified; 618.5 
prolapse of vaginal vault after hysterectomy; 618.6 vaginal enterocele, congenital or 
acquired; 618.7 old laceration of muscles of pelvic floor; 618.8 other specified genital 
prolapse; and 618.9 unspecified genital prolapse. Surgical procedures performed in 
association with the diagnosis of prolapse and categorized by ICD-9-CM code were 
grouped by prolapse compartment: anterior/posterior and apical. Concomitant 
hysterectomy and concomitant incontinence procedures, as well as other procedures, 
were also grouped, as shown in Table 1. It is noteworthy that ICD-9-CM codes for 
prolapse repair with graft or prosthesis were only introduced in October 2007 [14], and 
implementation of new codes is not immediate in some hospitals. 
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Gynecologists questionnaire 
We conducted a survey among members of the Portuguese Society of 
Urogynecology (PSUG), which is integrated in Portuguese Society of Gynecology 
(SPG) and the International Urogynecological Association (IUGA), as an affiliated 
society. The survey was aimed at reviewing the current practices on POP surgical 
procedures, including the use of meshes. It was also aimed at evaluating the impact of 
FDA 2011 communication on mesh use [10]. 
All PSUG members, gynecologists with special interest in urogynecology, were 
invited via email to participate in this survey. The initial invitation was sent in May 2013. 
Three waves of reminders were sent to non-respondents, and the survey was closed 
on November 2013.  
The questionnaire collected basic demographic and professional information, 
including sex, type of practice, and number of years in practice. Respondents who 
reported performing POP surgery were asked questions relating to the frequency of 
use of current POP procedures. Participants were asked about the use of meshes 
before and after 2011 FDA communication [10]. Then they were requested to estimate 
the total number of POP surgeries performed per year with vaginal and abdominal 
mesh. 
 
Statistical Methods 
Non-parametric tests (Kruskal-Wallis test) were used to study differences for age 
and length of hospital stay over the 13-year period. Pearson's chi-square test and 
Fisher’s exact test with exact p-values were used to study differences in proportions. 
Linear regression was used to investigate genital prolapse trends among age classes 
and trends in POP surgical procedures. Statistical analyses were performed at a level 
of significance of 5%. These analyses were conducted using SPSS Statistics for 
Windows, version 20.0 (IBM Corp., Armonk, New York, USA).   
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RESULTS 
Pelvic organ prolapse trends  
From 2000 to 2012, 46,819 discharges with diagnoses of principal or secondary 
genital prolapse (ICD-9-CM codes 618.xx) were registered in Portuguese public 
hospitals. As shown in Table 2,  the total number of hospital admissions due to genital 
prolapse increased from 2,368 to 4,941 (an increase of 105% from 2000 to 2012). 
As illustrated in Figure 1, the number of women hospitalizations with genital 
prolapse per 100,000 inhabitants (2000-2012) with ages in the ranges 55-64 and 65-74 
is clearly higher than in other age groups and increased over the study period. For 
women with ages <45 years old a slight increase in diagnosis of genital prolapse over 
the years is also seen, but it is considerably smaller than in other age groups.  
The mean age of women undergoing prolapse surgery was 63.1±11.5 years, with 
a significant mean age increase from 61.9 to 63.7 years over the 13-year study period 
(p<0.001). A significant decrease in the length of patient hospitalization was observed 
over the study period, with a median length stay of 6 days in 2000 (interquartile range 
4–8) and 4 days in 2012 (interquartile range 3–5), p<0.001.  
The most common surgical procedures considering all episodes with an ICD-9-
CM code diagnosis of genital prolapse were: repair of cystocele and/or rectocele; 
vaginal hysterectomy; stress urinary incontinence repair associated with genital 
prolapse; other repair of vagina; vaginal suspension and fixation; and operations on 
cul-de-sac (Figure 2). The number of native tissue anterior/posterior repairs (repair of 
cystocele and/or rectocele) increased significantly over time, comprising 1,140 repairs 
in 2000 and 3,280 in 2012. Thus, native tissue anterior/posterior repair was the most 
common type of surgery with 30,169 cases and presented one of the highest growths 
(Figure 2). Vaginal hysterectomy, repair of stress urinary incontinence, vaginal 
suspension and fixation, and operations on cul-de-sac also significantly increased from 
2000 to 2012 (Figure 2). The number of other repairs of vagina 
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(colpoperineoplasty/repair of old obstetric laceration of vagina), which were frequent 
surgeries in the past, decreased significantly during the study period (Figure 2). 
The number of obliterations of vaginal vault and obliterations of vagina, was 366 
and 169 respectively along the study period, and the number of other uterine 
suspensions (hysteropexy, Manchester operation, and plication of uterine ligaments) 
was 329. The amputation of cervix was seldom used (100 surgeries in 13 years). 
The registry of POP surgeries with meshes began only in 2007. This type of 
prolapse repair was recorded from 2007 to 2012 in a total of 1,468 cases, representing 
6% of total prolapse diagnosis. The cystocele repair with mesh was the most frequent 
surgical mesh procedure, with 700 cases and representing 48% of all surgical mesh 
procedures in this period.  
Regarding the anterior/posterior compartment, cystocele repair with mesh 
represented 10% of all cystocele repair surgeries, and rectocele repair with mesh 
represented 7% of all rectocele repair surgeries. However, the simultaneous repair of 
cystocele and rectocele with mesh was less frequent, representing only 3% (Figure 
3B). It is noted that anterior/posterior repairs with native tissue were not only more 
frequent but also showed higher growth than anterior/posterior repairs with vaginal 
meshes. Regarding the apical compartment, vaginal suspension and fixation with mesh 
represented 11% of all vaginal suspensions and fixation surgeries, and other 
operations on cul-de-sac with mesh represented only 1% of all other operations on cul-
de-sac (Figure 3C). 
The total number of mesh prolapse repairs increased significantly over time from 
5 mesh repairs in 2007 to 468 in 2011; from 2011 to 2012, a smaller increase to 497 
was registered (Figure 3A). When analyzed by vaginal compartment, mesh use for 
prolapse increased consistently apical compartment repair (Figure 3C); however, for 
anterior/posterior compartment repair, mesh use peaked in 2011 and then slightly 
declined in 2012 (Figure 3B).  
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Thus, and regarding the impact of 2011 FDA communication on the use of mesh 
for POP surgery, the following variations from 2011 to 2012 were observed: repair of 
cystocele graft or prosthesis from 243 to 223 (p=0.241); repair of rectocele with graft or 
prosthesis from 97 to 87 (p=0.377); repair of cystocele and rectocele with graft or 
prosthesis from 54 to 62 (p=0.524); vaginal suspension and fixation with graft or 
prosthesis from 73 to 122 (p=0.001); and other operations on cul-de-sac with graft or 
prosthesis from 1 to 3 (p=0.625). 
 
Current practices on pelvic organ prolapse surgery 
The questionnaire was sent to the 55 members of Portuguese Society of 
Urogynecology. With 46 respondents, the response rate was 84%. All of them reported 
performing prolapse surgery. The demographic characteristics of the respondents are 
summarized on Table 3. The survey respondents, representing a wide range of years 
of practice and practice type, reported performing a mean of 20.8 (min:0, max:100) 
POP vaginal mesh surgeries per year and a mean of  4.2 (min:0, max:30) POP 
abdominal mesh surgeries per year. 
For surgical procedures frequently used to treat utero-vaginal prolapse uterine 
descent, according to three/four stage descent, the principal choices were: vaginal 
hysterectomy with or without anterior/posterior repair (n=20, 45%), vaginal 
hysterectomy with sacrospinous ligament fixation (n=15, 33%), and vaginal 
hysterectomy associated to McCall culdoplasty (n=11, 24%); whereas, vaginal mesh 
repair not associated to hysterectomy was referred only by 1 of the respondents (2%).  
In the case of apical compartment vaginal vault prolapse (three/four stage), the 
principal choices were: anterior/posterior repair with sacrospinous fixation (n=15, 33%), 
abdominal sacrocolpopexy (n=11, 24%), and vaginal mesh repair (n=8, 17%).  
Among the respondents, anterior colporraphy (n=35, 76%), vaginal paravaginal 
repair (n=20, 43%), and anterior repair with vaginal mesh (n=8, 17%) were the most 
frequently used for anterior vaginal wall prolapse procedures. For the posterior wall 
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prolapse, the most frequently used procedures were: traditional posterior colporraphy 
(n=36, 78%), site-specific defect repair (n=23, 50%), and posterior repair with vaginal 
mesh (n=5, 11%).  
It was observed that 57% (26/46) of the respondents performed POP vaginal 
mesh surgery. Of those, 11 (42%) never performed sacrospinous ligament fixation and 
16 (62%) never performed vaginal paravaginal repair. While from those who did not 
perform POP vaginal mesh surgery, only 4 (20%) never undertook sacrospinous 
ligament fixation (p=0.072) and all of them reported having done vaginal paravaginal 
repair (p<0.001), with 16 (80%) referring that it is performed frequently. 
After 2011 FDA communication, 27% (7/26) of the respondents reported having 
changed POP surgical procedures with vaginal meshes, whereas 73% (19/26) still use 
mesh with no change in practice. From those that changed their surgical practice with 
vaginal meshes, 4 (57%) reported a reduced use of meshes, 2 (29%) stopped using 
meshes, and 1 (14%) mentioned other actions. There was no statistically significant 
difference among male and female gynecologists, years in practice, practice type, and 
number of POP vaginal and abdominal mesh surgeries performed per year, between 
gynecologists who changed their practice after FDA’s communication and those who 
did not change.   
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DISCUSSION 
The total number of hospital admissions due to POP registered in Portugal 
increased 105% from 2000 to 2012. This increased number of diagnoses can be 
explained not only by a greater awareness of the population (which leads women to 
seek medical help more promptly), but also by a greater awareness of professionals 
and the availability of better surgical therapeutic techniques. 
Studies conducted in other countries exhibited similar results [15,16]. In the 
Netherlands, hospital admissions due to uterovaginal prolapse increased 65% during 
the period 1997-2009 [16]. In the US, the number of women undergoing prolapse 
surgeries, is also reported to have slightly increased from 1998-2007 [15]. However, a 
more comprehensive US analysis from 1979-2006 [17] showed a different trend, 
reporting that the number of women undergoing prolapse procedures in the US, 
decreased 23.6% from 1979-2006. Nevertheless, when stratified by age, the age-
adjusted rates for inpatient procedures for prolapse remained stable for women with 
ages ≥52 years and decreased by two-thirds, for women with ages <52 years. 
In this study, the number of women subjected to prolapse repair surgeries in the 
age groups 55-64 years and 65-74 years had the largest increase over 13-year period, 
whereas women with ages <45 years only showed a slight increase. Additionally, the 
mean age of women undergoing prolapse surgery increased from 2000 to 2012, which 
is consistent with findings from other studies [17]. It is, however, noteworthy that even 
though the age of women subjected to prolapse surgery increased, the length of 
hospitalization decreased, which is in line with studies from other countries [17]. This 
increase in mean age of women undergoing prolapse surgery can be explained by 
several factors: the population is aging; there is increased awareness among older 
women; and surgical techniques evolved, providing now better results in these patients. 
In Portugal, women with ages ≥65 years represented already 19.4% of the population 
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in 2012 [18], and in line with this aging population trend, Luber et al [19] estimate that 
by 2030 diagnosis of pelvic floor disorders will increase substantially. 
Our findings indicate that surgical trends in treating POP evolved in the last 13 
years in Portugal. The repair of cystocele and/or rectocele with native tissues was the 
most common POP surgery, showing the greatest growth; this is in accordance with 
the study conducted in the Netherlands from 1997 to 2009, which also showed a 
marked increase of anterior and/or posterior colporraphy [16]. 
 Vaginal hysterectomy was the second most common type of surgery, with a 
substantial growth over the study period. In a comparable study from the UK, regarding 
women with uterovaginal prolapse, the procedure of choice was vaginal hysterectomy 
and repair [20]. Comparing our Portuguese data on vaginal hysterectomy with data 
from other countries, we noticed that some studies mention decreases of vaginal 
hysterectomy over the years [21,22]. Ping Wu et al. reported changing trends of 
surgical procedures used for uterine prolapse in Taiwan from 1997-2007, with a trend 
for increased use of uterine suspension with uterine preservation, and a decreasing 
trend for overall hysterectomy [22]. Detollenaere et al. [16] in the Netherlands referred 
that vaginal hysterectomy was the most frequently performed surgical intervention for 
uterine descent, however a trend toward preserving the uterus was observed. 
Concomitant anti-incontinence surgery was the third most frequent type of 
surgery, also with a substantial growth over the study period. Rogo-Gupta et al. [23],  
identified 42.6% women undergoing concurrent incontinence surgery when analyzing 
women who underwent POP repair. A possible explanation for this concomitant POP 
surgery is the fact that our dataset comprises not only inpatient data, but also 
ambulatory surgical procedures. This is in line with the work of Erekson [23], who 
reported an increased number of women undergoing ambulatory surgical procedures 
for pelvic floor disorders from 1996 to 2006 in the US. 
The use of surgical mesh for POP repair in Portugal is very limited, in comparison 
with traditional non-mesh repair. Nonetheless, the use of surgical mesh for POP repair 
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has clearly increased from 2007 to 2011, with a smaller increase from 2011 to 2012. 
These increases are not entirely in agreement with other studies. Here, we identified a 
plateau of mesh procedures in 2011, whereas in other countries, vaginal mesh use for 
POP repair has been found to stabilize around 2007-2009 [5,24]. Nevertheless, the use 
of meshes in POP repair in Portugal is clearly smaller than the use of meshes identified 
in other studies [5,23-25], and therefore the trends observed in the US, are not 
comparable to data from Portugal and or even the Netherlands [16], since here mesh 
use is not so widespread. 
When mesh use is analyzed by prolapse compartment there is a marked and 
significant increase of mesh use for anterior/posterior repairs, with a peak in 2011 and 
a slight decrease after 2011 to 2012. For apical compartment repair this increase is 
constant and significant from 2007 to 2012. However, it is important to note that the 
inadequacies of the current coding practices impair a more precise analysis. In fact, 
apical compartment mesh repair (vaginal suspension and fixation and operations on 
cul-de-sac) uses ICD-9-CM codes that do not allow categorization as abdominal or 
vaginal mesh surgery. This has practical implications, since the codes can also reflect 
abdominal prolapse repair, which are out of scope of the FDA communications. It is 
possible that a transition from vaginal to abdominal meshes is disguised in this 
continuous increase mesh use for apical repairs. Therefore, in order to obtain more 
data that might help to clarify the surgical management of POP and the impact of FDA 
communications on surgical practices in Portugal, we decided to conduct a survey of 
among the members of PSUG. 
Among the gynecologists who accepted to answer the questionnaire, different 
surgeries were selected as procedures frequently used to treat POP in the various 
compartments; but POP surgeries with vaginal mesh were rarely referred as 
procedures of choice. These findings are mostly in agreement with previous studies 
[16,20], and reflect the wide variety of procedures implemented in the surgical 
treatment of POP, but also the limited use of vaginal meshes. 
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About half the respondents (57%) performed POP vaginal mesh surgery. 
Interestingly, among those there was a higher proportion of gynecologists who never 
performed vaginal paravaginal repair or sacrospinous ligament fixation. This may 
suggest that gynecologists who perform POP vaginal mesh surgery are less 
familiarized with traditional non-mesh procedures. 
Only a small proportion of respondents (27%) who performed POP vaginal mesh 
surgery, actually reported having changed their practice after FDA 2011 
communication. These findings suggest that the impact of FDA communication was 
less pronounced among Portuguese gynecologists. In a previous study conducted in 
the US, only 21% of respondents reported not having change their practices [11]. It is, 
however, noteworthy that in Portugal the overall use of vaginal mesh is much smaller 
than in the US, which may justify why Portuguese gynecologists did not felt the need to 
change their practices. 
The main weakness of this study is transversal to all studies that comprise 
surveys: they depend on the accuracy and objectivity (or lack of it) of respondents. 
However, in this case the response rate was remarkably high (84%), which is an 
indicative that the patterns identified here are representative of the population. As in 
other studies, we also had to face the limitations of ICD-9-CM coding. This coding 
system does not distinguish the type of apical suspension performed, and does not 
consistently categorizes mesh procedures by abdominal or vaginal route. This system 
allows, however, classification of the type of mesh used (synthetic vs. biological), but 
this property was not registered at Portuguese hospitals, and therefore it was not 
possible to assess the types of meshes used. Additionally, mesh use might have been 
underreported in the first years after it was introduced in the coding system (2007–
2008). Nevertheless, the main trend of increased use of meshes up to 2011 cannot be 
only attributed to this underreporting issue, since the growth in mesh use was 
continuous for several years. 
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The main strength of this study is the use of the Portuguese National Medical 
Registry database, which provides nationally representative and validated data. 
Besides, the time period under analysis is fairly long (13 years), allowing a 
comprehensive characterization of the evolution of surgical management of POP in 
Portugal. 
In conclusion, POP surgical procedures conducted in Portugal greatly increased 
in the last decade. The use of surgical meshes is still limited, but despite FDA safety 
communication, it has increased over the years. Nonetheless, mesh use has only slight 
increased from 2011 to 2012, and therefore further analyses will be required to assess 
the full impact of FDA safety communications.    
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FIGURE LEGENDS 
 
Figure 1 - Number of hospitalizations with genital prolapse diagnosis per 100,000 inhabitants 
(2000-2012), stratified by age groups. 
  
Figure 2 - Trends in surgical procedures for genital prolapse. 
 
Figure 3 - Trends in mesh use for prolapse repair. (A) Overall and by compartment mesh use 
trends. (B) Trends for anterior/posterior compartment prolapse repairs with and without mesh. 
(C) Trends for apical compartment prolapse procedures with and without mesh.   
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TABLES 
Table 1 - Selected surgical procedures considering all episodes with an ICD-9-CM code of genital 
prolapse 
Procedure description ICD-9-CM Code 
Anterior/Posterior compartment repair  
         Repair of cystocele and rectocele 70.50 
         Repair of cystocele 70.51 
         Repair of rectocele 70.52 
         Repair of cystocele and rectocele with graft or prosthesis*” 70.53 
         Repair of cystocele with graft or prosthesis*” 70.54 
         Repair of rectocele with graft or prosthesis*” 70.55 
Apical compartment repair  
        Repair of uterine supporting structures - interposition operation 69.21 
         Other uterine suspension (hysteropexy, Manchester operation and plication of the uterine ligaments) 69.22 
         Other repair of uterus and supporting structures 69.29 
         Other operations on supporting structures of uterus 69.98 
         Vaginal suspension and fixation 70.77 
         Vaginal suspension and fixation with graft or prosthesis*” 70.78 
         Other operations on cul-de-sac 70.92 
         Other operations on cul-de-sac with graft or prosthesis*” 70.93 
Hysterectomy procedure  
         Subtotal abdominal hysterectomy  68.3 
         Laparoscopic supracervical hysterectomy (LSH) 68.31 
         Other and unspecified subtotal abdominal hysterectomy 68.39 
         Total abdominal hysterectomy 68.4 
         Laparoscopic total abdominal hysterectomy 68.41 
         Other and unspecified total abdominal hysterectomy 68.49 
         Laparoscopically assisted vaginal hysterectomy (LAVH) 68.51 
         Other and unspecified vaginal hysterectomy 68.59 
         Other and unspecified hysterectomy 68.9 
Incontinence procedure  
         Plication of urethrovesical junction 59.3 
         Suprapubic sling operation 59.4 
         Retropubic urethral suspension 59.5 
         Paraurethral suspension  59.6 
         Levator muscle operation for urethrovesical suspension  59.71 
         Other repair of urinary stress incontinence 59.79 
Others procedures  
        Repair of rectum  48.7 
        Amputation of cervix 67.4 
        Obliteration and total excision of vagina (vaginectomy) 70.4 
        Vaginal reconstruction 70.62 
        Vaginal reconstruction  with graft or prosthesis*” 70.64 
        Suture of laceration of vagina 70.71 
        Other repair of vagina (colpoperineoplasty/repair of old obstetric laceration of vagina) 70.79 
        Obliteration of vaginal vault (LeFort operation) 70.8 
        Other operations on vagina 70.91 
        Repair of vulva and perineum 71.7 
        Suture of laceration of vulva or perineum 71.71 
        Other repair of vulva and perineum/repair of old obstetric laceration of vulva or perineum 71.79 
 
*Modifier indicating insertion of biological graft (ICD-9 code 70.94) 
"Modifier indicating insertion of synthetic graft  (ICD-9 code 70.95)  
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Table 2 - Episodes with a diagnosis of genital prolapse (ICD-9-CM code 618.xx) by discharge 
year 
 
  
Type of diagnosis 
(n) 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 
               
Principal diagnosis 
of genital prolapse 
1986 1929 2011 2345 2599 2734 3014 3093 3278 3723 3971 4089 4069 38841 
               
Secondary 
diagnosis of genital 
prolapse 
382 437 418 472 595 618 644 621 718 717 731 753 872 7978 
Total 2368 2366 2429 2817 3194 3352 3658 3714 3996 4440 4702 4842 4941 46819 
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Table 3. Demographic characteristics of the members of the Portuguese society of 
urogynecology who responded to the questionnaire. 
 
Characteristics 
Respondents, n (%) 
(n=46) 
Gender  
      Male 16 (35) 
      Female 30 (65) 
  
Years in practice  
      < 10 12 (26) 
      10 to 20 21 (46) 
      > 20 13 (28) 
  
Type of practice  
     Public Hospital 13 (28) 
     Private Hospital 3 (7) 
     Both 30 (65) 
  
POP vaginal mesh surgeries per year  
     0 20 (43) 
     1-30 17 (37) 
     > 30 9 (20) 
  
POP abdominal mesh surgeries per year  
     0 13 (28) 
     1-10 29 (63) 
     > 10 4 (9) 
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